



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/894,423	06/28/2001	Ronald H. Chiarello	SYNGEN-06067	6875
23535	7590 02/13/2006		EXAMINER	
MEDLEN &	& CARROLL, LLP	QIAN, CELINE X		
SUITE 350	DSIREEI	ART UNIT	PAPER NUMBER	
SAN FRANCISCO, CA 94105			1636	
			DATE MAILED: 02/13/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

ور ت

	Application No.	Applicant(s)		
	09/894,423	CHIARELLO ET AL.		
Office Action Summary	Examiner	Art Unit		
	Celine X. Qian Ph.D.	1636		
The MAILING DATE of this communication appeared for Reply	pears on the cover sheet with the o	correspondence address		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.4 after SIX (6) MONTHS from the mailling date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	OATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on <u>03 J</u>	lanuary 2006.			
2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.		
Disposition of Claims				
4) Claim(s) 1 and 4 is/are pending in the application 4a) Of the above claim(s) is/are withdration 5) Claim(s) is/are allowed. 6) Claim(s) 1 and 4 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	awn from consideration.			
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on 6/28/01,4/7/03 is/are: Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	a) \boxtimes accepted or b) \square objected to drawing(s) be held in abeyance. Section is required if the drawing(s) is ob-	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date S. Patent and Trademark Office	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:			

Application/Control Number: 09/894,423

Art Unit: 1636

DETAILED ACTION

Claims 1 and 4 are pending in the application.

This Office Action is in response to the Amendment filed on 1/3/06.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/3/06 has been entered.

Response to Amendment

The rejection of claims 1 and 4 under 35 U.S.C. 102 has been withdrawn in light of Applicant's amendment.

The rejection of claims 1 and 4 under 35 U.S.C. 112 1st paragraph has been withdrawn in light of Applicant's amendment.

Claims 1 and 4 are rejected under 35 U.S.C. 103 (a) for reasons discussed below.

New Grounds of Rejection Necessitated by Amendment

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1 and 4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Snitman, in view of Vinayak et el (for same reasons as set forth of the record mailed on 9/30/02 and 6/17/03).

Snitman teaches reacting an oligonucleotide bound at its 3' end to a solid support with the liner [(CH₃)₂CH]₂NP(OCH₃)O(CH₂)₈NH(DMT) wherein DMT is a dimethoxytrityl group, to form a 5' amine functionalized oligonucleotide. This is then reacted with fluorescein isothiocyanate. In the process of reacting this with the fluorescein isothiocyanate, the protected amine group loses its protective DMT group. (See entire document, especially col.3, line 17-col. 4, line 16 and col.8, line 67-col.9, line 6). However, Snitman does not teach a linker that is identical to the linkers recited in the claims. Specifically, the moiety on the phosphate oxygen is a methyl group and not CH₂CH₂CHN.

Vinayak et al. teach labeling an oligonucleotide bound at its 3' end to a polystyrene support by reacting the oligonucleotide with an amino-linker phosphoramidite reagent. The protected amino group is detritylated (thus deprotected) then reacted with an activate label, such as TAMRA-CO₂H. Other labels taught for use in the methods include: 6-FAM, rhodamines and fluoresciens. (See entire document, especially col. 5, lines 46-63, col. 11, lines 16-58, cols. 13-16, col.19, Example 3, col. 20, Example 5 and col.22, Example 9). Absent evidence from the contrary it is assumed that the amino-linker phosphoramidite reagent is the same as shown in col.11, lines 30-40 except having DMT rather than MMT as the protecting group. This assumption is grounded in the knowledge that commercially-available DNA synthesis reagents typically employ DMT, that both groups are acid liable protecting groups and also in the

Art Unit: 1636

summary of the steps of a synthesis cycle taught by Vinayak et al. in col. 10 lines 46-col. 11, line 15.

It would have been obvious to one of ordinary skill in the art to combined teaching of both Snitman and Vinayak and reach the method of labeling oligonucleotides using the claimed bifunctional linker. The ordinary artisan would have been motivated to do so because using any moiety at that position that could undergo beta-elimination would have worked for the method taught by Snitman. As such, the methyl is an equivalent of the CH₂CH₂CHN. Absent evidence from the contrary, one of ordinary skilled in the art would have reasonable expectation of success to use CH₂CH₂CHN instead of methyl group for the bifunctional linker. Therefore, the invention would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X. Qian Ph.D. whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/894,423 Page 5

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Celine X Qian Ph.D. Examiner Art Unit 1636

CELIAN QIAN
PATENT EXAMINER